Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment, Net

Equipment, Net

9 Months Ended

Sep. 30, 2014

5. Equipment, Net



	September 30,		December 31,
	2014		2013

Furniture and fixtures	$	64,689	$	59,133
Office equipment		57,182		41,752
Lab and computer equipment		425,195		425,195
Leasehold improvements		129,009		119,841

Total equipment		676,075		645,921
Less: Accumulated depreciation and amortization		(603,167)		(580,749)

Net carrying amount	$	72,908	$	65,172

Depreciation and amortization expense was $3,744 and $9,645 for the three months ended September 30, 2014 and 2013, respectively, and $22,418 and $28,196 for the nine months ended September 30, 2014 and 2013, respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details